Precipio (Precipio) GF Value : $34.93 (As of May. 05, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Precipio GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-05), Precipio's share price is $5.80. Precipio's GF Value is $34.93. Therefore, Precipio's Price-to-GF-Value for today is 0.17.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Precipio is Possible Value Trap, Think Twice.

Precipio (NAS:PRPO) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Precipio's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	5.80	/	34.93
	=	0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precipio GF Value Related Terms

Thank you for viewing the detailed overview of Precipio's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Precipio (Precipio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Science Park, New Haven, CT, USA, 06511

Website

https://www.precipiodx.com

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.

Executives

Richard A Sandberg	director	330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet	officer: Chief Operations Officer	33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli	director, officer: Chief Executive Officer	14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage	officer: Chief Financial Officer	56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen	director, 10 percent owner	C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte	director
Robert Patzig	director	THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther	director	21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman	director	C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger	officer: Chief Financial Officer	C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher	director	587 PATROL RD, WOODSIDE CA 94062
Mark Rimer	director, 10 percent owner	C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511